{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:57:01Z","timestamp":1787187421125,"version":"build-2736575974"},"reference-count":36,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002543","name":"Pusan National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>We investigated the appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors (XOIs) as first\u2010line urate\u2010lowering therapy (ULT) in patients with gout. This was a nationwide population\u2010based retrospective cohort study using the Korean Health Insurance Review and Assessment database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with gout aged \u226520\u2009years who were newly initiated on XOIs, such as allopurinol or febuxostat, from July 2015 to June 2017 and received these medications for \u22656\u2009months were analyzed and followed up until June 2019. Persistence of XOIs was compared according to the 6\u2010month duration of colchicine prophylaxis. For additional subgroup analysis, we also compared the persistence of XOIs according to the 3\u2010month duration of colchicine prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study included 43\u2009926 patients. The frequencies of patients with gout receiving colchicine prophylaxis for \u22656\u2009months and \u22653\u2009months were 6.3% and 7.6%, respectively. Allopurinol (65.2%) was prescribed more frequently than febuxostat (34.8%). During the study period, 23\u2009475 patients (53.4%) stopped using XOIs. Colchicine prophylaxis for \u22656\u2009months did not significantly reduce the risk of XOI discontinuation in multivariable Cox regression models. Colchicine prophylaxis for \u22653\u2009months was significantly associated with a lower risk of non\u2010persistence to XOIs after adjusting for confounding factors (hazard ratio\u2009=\u20090.95, <jats:italic>p<\/jats:italic>\u2009=\u2009.041).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data suggest that at least 3\u2009months of colchicine prophylaxis may be more appropriate than at least 6\u2009months in terms of maximizing the persistence of XOIs in patients with gout.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.14825","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T06:55:34Z","timestamp":1689058534000},"page":"1770-1778","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first\u2010line urate\u2010lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-0410","authenticated-orcid":false,"given":"Min Wook","family":"So","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Pusan National University School of Medicine  Yangsan South Korea"},{"name":"Division of Rheumatology, Department of Internal Medicine Pusan National University Yangsan Hospital  Yangsan South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u2010Ran","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Pusan National University School of Medicine  Yangsan South Korea"},{"name":"Division of Rheumatology, Department of Internal Medicine Pusan National University Hospital  Busan South Korea"},{"name":"Biomedical Research Institute Pusan National University Hospital  Busan South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-3978","authenticated-orcid":false,"given":"Seung\u2010Geun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Pusan National University School of Medicine  Yangsan South Korea"},{"name":"Division of Rheumatology, Department of Internal Medicine Pusan National University Hospital  Busan South Korea"},{"name":"Biomedical Research Institute Pusan National University Hospital  Busan South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2022.29.3.140"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2020.27.2.78"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204463"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2013.04.003"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2020.27.3.174"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex156"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14266"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12422"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05161-w"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S97927"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.01.008"},{"key":"e_1_2_10_16_1","first-page":"799","article-title":"Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea","volume":"46","author":"Sung CS","year":"2017","journal-title":"Int J Epidemiol"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.5.718"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1483293"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1514-4"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2016.02.006"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2012.01719.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1549-6"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.03.012"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05265-3"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1125"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S284759"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.09.007"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1170914"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes431"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2659"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076182"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140588"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2823-8"},{"key":"e_1_2_10_34_1","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel AA","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.05.2774"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21773"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu157"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T08:47:44Z","timestamp":1693817264000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.14825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/1756-185X.14825"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.14825","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"2023-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}